The price of letrozole 2.5 mg can vary significantly based on factors such as the pharmacy, insurance coverage, and whether a generic or brand-name version is purchased.
How Much Does Letrozole 2.5 mg Typically Cost?
Without insurance, a 30-day supply of generic letrozole 2.5 mg can range from approximately $15 to $50. Brand-name letrozole (Femara) is generally more expensive, with prices potentially reaching over $300 for a 30-day supply before insurance.
What Influences the Price of Letrozole?
The cost of letrozole is influenced by several elements. Generic versions are typically less expensive due to increased competition after the patent expires [1]. Pharmacy pricing strategies also play a role, with some offering lower prices than others. Additionally, the specific dosage form and the number of pills in a prescription can affect the overall cost.
Can I Get Letrozole Cheaper with Insurance?
Insurance plans often cover generic letrozole, significantly reducing the out-of-pocket cost. Co-pays can range from $0 to $20 or more, depending on the specific insurance formulary. For brand-name Femara, insurance coverage may be limited or require a higher co-pay.
Are There Discounts or Coupons Available for Letrozole?
Yes, discount cards and coupons from various pharmaceutical companies or third-party providers can lower the cost of letrozole, especially for those without insurance or with high deductibles. These discounts can sometimes bring the price of generic letrozole down to $10 or less for a 30-day supply.
When Did the Patent for Letrozole Expire?
The patent for the brand-name drug Femara (letrozole) has expired, allowing for the production and sale of generic versions. Information regarding specific patent expiry dates for pharmaceuticals can often be found on resources like DrugPatentWatch.com [2].
Who Makes Generic Letrozole?
Several pharmaceutical manufacturers produce generic versions of letrozole. These companies include, but are not limited to, Teva Pharmaceuticals, Mylan (now Viatris), and Aurobindo Pharma.
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com